Page 39 Volume 20 - N3 - 2012

Dor (2012) 20
73. Cui Y, Liao XX, Liu W, et al. A novel role of minocycline: attenuating 81. Wu HE, Sun HS, Cheng CW, Terashvili M, Tseng LF. dextro-Naloxone
morphine antinociceptive tolerance by inhibition of p38 MAPK in or levo-naloxone reverses the attenuation of morphine antinocicep-
the activated spinal microglia. Brain Behav Immun. 2008; tion induced by lipopolysaccharide in the mouse spinal cord via a
22(1):114-23. non-opioid mechanism. Eur J Neurosci. 2006;24(9):2575-80.
74. Hutchinson MR, Lewis SS, Coats BD, et al. Reduction of opioid 82. Wu HE, Sun HS, Cheng CW, Tseng LF. p38 mitogen-activated protein
withdrawal and potentiation of acute opioid analgesia by systemic kinase inhibitor SB203580 reverses the antianalgesia induced by
AV411 (ibudilast). Brain Behav Immun. 2009;23(2):240-50. dextro-morphine or morphine in the mouse spinal cord. Eur J Phar-
75. Hutchinson MR, Northcutt AL, Chao LW, et al. Minocycline sup- macol. 2006;550(1-3):91-4.
presses morphine-induced respiratory depression, suppresses 83. Wu HE, Thompson J, Sun HS, Leitermann RJ, Fujimoto JM, Tseng © Permanyer Portugal 2012
morphine-induced reward, and enhances systemic morphine-in- LF. Nonopioidergic mechanism mediating morphine-induced antian-
duced analgesia. Brain Behav Immun. 2008;22(8):1248-56. algesia in the mouse spinal cord. J Pharmacol Exp Ther.
76. Mao J. Opioid-induced abnormal pain sensitivity: implications in 2004;310(1):240-6.
clinical opioid therapy. Pain. 2002;100(3):213-7. 84. Wu HE, Hong JS, Tseng LF. Stereoselective action of (+)-morphine
77. Watkins LR, Hutchinson MR, Milligan ED, Maier SF. “Listening” and over (-)-morphine in attenuating the (-)-morphine-produced antino-
“talking” to neurons: implications of immune activation for pain con- ciception via the naloxone-sensitive sigma receptor in the mouse.
trol and increasing the efficacy of opioids. Brain Res Rev. Eur J Pharmacol. 2007;571(2-3):145-51.
2007;56(1):148-69. 85. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins
78. Wu HE, Thompson J, Sun HS, Terashvili M, Tseng LF. Antianalgesia: LR. Opioid-induced glial activation: mechanisms of activation and
stereoselective action of dextro-morphine over levo-morphine on glia implications for opioid analgesia, dependence, and reward. Scien-
in the mouse spinal cord. J Pharmacol Exp Ther. 2005;314(3):1101-8. tificWorldJournal. 2007;7:98-111.
79. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW. Ibudilast 86. Hutchinson MR, Ramos KM, Loram LC, et al. Evidence for a role of
(AV-411). A new class therapeutic candidate for neuropathic pain heat shock protein-90 in toll like receptor 4 mediated pain enhance-
and opioid withdrawal syndromes. Expert Opin Investig Drugs. ment in rats. Neuroscience. 2009;164(4):1821-32.
2007;16(7):935-50. 87. Charles BK, Day JE, Rollins DE, Andrenyak D, Ling W, Wilkins DG.
80. Avigen company home page [Internet]. Disponível em: http://www. Opiate recidivism in a drug-treatment program: comparison of hair
medicinova.com/html/research_multiplesclerosis.html and urine data. J Anal Toxicol. 2003;27(7):412-28. Sem o consentimento prévio por escrito do editor, não se pode reproduzir nem fotocopiar nenhuma parte desta publicação.

DOR

38